ImmunityBio Shares Hit 52-Week high After FDA Meeting on Anktiva

Dow Jones01-20

By Chris Wack

ImmunityBio shares were 36% higher, at $7.52, after the company said it recently held a Type B End-of-Phase meeting with the Food and Drug Administration regarding its supplemental Biologics License Application for Anktiva plus Bacillus Calmette-Guerin in non-muscle invasive bladder cancer with papillary tumors.

The stock hit its 52-week high of $7.98 earlier in the session, and is 163% higher in the past 12 months.

The clinical-stage immunotherapy company said the FDA recommended that the company provide additional information for its consideration to support a potential resubmission of the sBLA initially submitted in 2025 for the papillary indication.

ImmunityBio said it has compiled the requested information and will submit it within the next 30 days. This additional information doesn't contemplate the initiation or design of a new clinical trial.

This submission follows a productive face-to-face meeting with senior FDA officials, the company said, during which the regulatory path forward for Anktiva in papillary NMIBC was collaboratively defined. Topics included current standards of care, challenges associated with chemotherapy, patient management considerations and perspectives on the interpretation of the company's data.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

January 20, 2026 10:50 ET (15:50 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

1

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2604112725?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-20 23:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604112725","market":"sh","top_or_hot":-1,"title":"ImmunityBio Shares Hit 52-Week high After FDA Meeting on Anktiva","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  ImmunityBio shares were 36% higher, at $7.52, after the company said it recently held a Type B End-of-Phase meeting with the Food and Drug Administration regarding its supplemental Biologics License Application for Anktiva plus Bacillus Calmette-Guerin in non-muscle invasive bladder cancer with papillary tumors. \n</p>\n<p>\n  The stock hit its 52-week high of $7.98 earlier in the session, and is 163% higher in the past 12 months. \n</p>\n<p>\n  The clinical-stage immunotherapy company said the FDA recommended that the company provide additional information for its consideration to support a potential resubmission of the sBLA initially submitted in 2025 for the papillary indication. \n</p>\n<p>\n  ImmunityBio said it has compiled the requested information and will submit it within the next 30 days. This additional information doesn't contemplate the initiation or design of a new clinical trial. \n</p>\n<p>\n  This submission follows a productive face-to-face meeting with senior FDA officials, the company said, during which the regulatory path forward for Anktiva in papillary NMIBC was collaboratively defined. Topics included current standards of care, challenges associated with chemotherapy, patient management considerations and perspectives on the interpretation of the company's data. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 20, 2026 10:50 ET (15:50 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunityBio Shares Hit 52-Week high After FDA Meeting on Anktiva</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunityBio Shares Hit 52-Week high After FDA Meeting on Anktiva\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-20 23:50</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  ImmunityBio shares were 36% higher, at $7.52, after the company said it recently held a Type B End-of-Phase meeting with the Food and Drug Administration regarding its supplemental Biologics License Application for Anktiva plus Bacillus Calmette-Guerin in non-muscle invasive bladder cancer with papillary tumors. \n</p>\n<p>\n  The stock hit its 52-week high of $7.98 earlier in the session, and is 163% higher in the past 12 months. \n</p>\n<p>\n  The clinical-stage immunotherapy company said the FDA recommended that the company provide additional information for its consideration to support a potential resubmission of the sBLA initially submitted in 2025 for the papillary indication. \n</p>\n<p>\n  ImmunityBio said it has compiled the requested information and will submit it within the next 30 days. This additional information doesn't contemplate the initiation or design of a new clinical trial. \n</p>\n<p>\n  This submission follows a productive face-to-face meeting with senior FDA officials, the company said, during which the regulatory path forward for Anktiva in papillary NMIBC was collaboratively defined. Topics included current standards of care, challenges associated with chemotherapy, patient management considerations and perspectives on the interpretation of the company's data. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 20, 2026 10:50 ET (15:50 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2604112725","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2604112725","pubTimestamp":1768924200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"ImmunityBio shares were 36% higher, at $7.52, after the company said it recently held a Type B End-of-Phase meeting with the Food and Drug Administration regarding its supplemental Biologics License Application for Anktiva plus Bacillus Calmette-Guerin in non-muscle invasive bladder cancer with papillary tumors.The stock hit its 52-week high of $7.98 earlier in the session, and is 163% higher in the past 12 months.The clinical-stage immunotherapy company said the FDA recommended that the company provide additional information for its consideration to support a potential resubmission of the sBLA initially submitted in 2025 for the papillary indication.This submission follows a productive face-to-face meeting with senior FDA officials, the company said, during which the regulatory path forward for Anktiva in papillary NMIBC was collaboratively defined. Topics included current standards of care, challenges associated with chemotherapy, patient management considerations and perspectives on","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IBRX":"ImmunityBio, Inc."},"translate_title":"FDA就Anktiva召开会议后，ImmunityBio股价触及52周高点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":0.9},"content_text":"By Chris Wack \n\n\n \n\n\n  ImmunityBio shares were 36% higher, at $7.52, after the company said it recently held a Type B End-of-Phase meeting with the Food and Drug Administration regarding its supplemental Biologics License Application for Anktiva plus Bacillus Calmette-Guerin in non-muscle invasive bladder cancer with papillary tumors. \n\n\n  The stock hit its 52-week high of $7.98 earlier in the session, and is 163% higher in the past 12 months. \n\n\n  The clinical-stage immunotherapy company said the FDA recommended that the company provide additional information for its consideration to support a potential resubmission of the sBLA initially submitted in 2025 for the papillary indication. \n\n\n  ImmunityBio said it has compiled the requested information and will submit it within the next 30 days. This additional information doesn't contemplate the initiation or design of a new clinical trial. \n\n\n  This submission follows a productive face-to-face meeting with senior FDA officials, the company said, during which the regulatory path forward for Anktiva in papillary NMIBC was collaboratively defined. Topics included current standards of care, challenges associated with chemotherapy, patient management considerations and perspectives on the interpretation of the company's data. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 20, 2026 10:50 ET (15:50 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604112725","isCrawlerRequest":true}